| Year |
Citation |
Score |
| 2023 |
Kunwor R, Silver DP, Abu-Khalaf M. PARP Inhibitors for the Treatment of BRCA1/2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis. Hematology/Oncology and Stem Cell Therapy. 16: 186-196. PMID 37023220 DOI: 10.56875/2589-0646.1033 |
0.32 |
|
| 2022 |
Abu-Khalaf M, Wang C, Zhang Z, Luo R, Chong W, Silver DP, Fellin F, Jaslow R, Lopez A, Cescon T, Jiang W, Myers R, Wei Q, Li B, Cristofanilli M, et al. Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism. Cancers. 14. PMID 35740538 DOI: 10.3390/cancers14122872 |
0.353 |
|
| 2021 |
Bashir Hamidu R, Asif B, Lavu H, Kowalski T, Silver DP. Duodenal and Biliary Obstruction due to Extrinsic CompressionDuodenal and Biliary Obstruction due to Extrinsic Compression by Recurrent Lobular Breast Carcinoma: A Case Report. Case Reports in Gastroenterology. 15: 869-876. PMID 34720837 DOI: 10.1159/000518874 |
0.367 |
|
| 2021 |
Luo R, Chong W, Wei Q, Zhang Z, Wang C, Ye Z, Abu-Khalaf MM, Silver DP, Stapp RT, Jiang W, Myers RE, Li B, Cristofanilli M, Yang H. Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer. Npj Breast Cancer. 7: 72. PMID 34075047 DOI: 10.1038/s41523-021-00278-w |
0.357 |
|
| 2020 |
Wang C, Mu Z, Ye Z, Zhang Z, Abu-Khalaf MM, Silver DP, Palazzo JP, Jagannathan G, Fellin FM, Bhattacharya S, Jaslow RJ, Tsangaris TN, Berger A, Neupane M, Cescon TP, et al. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. Breast Cancer Research and Treatment. PMID 32367460 DOI: 10.1007/S10549-020-05662-X |
0.325 |
|
| 2020 |
Wang C, Ye Z, Zhang Z, Abu-Khalaf M, Silver D, Lopez A, Fellin F, Bhattacharya S, Jaslow R, Yao K, Toorkey D, Pancholy N, Myers R, Yang H. Abstract P6-10-23: Presence of circulating tumor cell clusters and elevated platelet counts interactively predict disease progression in advanced-stage breast cancer patients Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-10-23 |
0.311 |
|
| 2020 |
Bhattacharya S, Schiewer M, Murphy RC, Anne PR, Simone N, Ad VB, Khalaf MA, Silver DP, Jaslow R, Fellin FM, Zibelli AM, Lopez AM, Berger A, Tsangaris TN, Lazar MA, et al. Abstract OT2-03-02: A pilot trial of hyperthermia in combination with olaparib in breast cancer patients with chest wall recurrences Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Ot2-03-02 |
0.341 |
|
| 2019 |
Telli ML, Chu C, Badve SS, Vinayak S, Silver DP, Isakoff SJ, Kaklamani V, Gradishar W, Stearns V, Connolly RM, Ford JM, Gruber JJ, Adams S, Garber J, Tung N, et al. Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31796517 DOI: 10.1158/1078-0432.Ccr-19-0664 |
0.388 |
|
| 2018 |
Ye Z, Wang C, Wan S, Mu Z, Zhang Z, Abu-Khalaf MM, Fellin FM, Silver DP, Neupane M, Jaslow RJ, Bhattacharya S, Tsangaris TN, Chervoneva I, Berger A, Austin L, et al. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. European Journal of Cancer (Oxford, England : 1990). 106: 133-143. PMID 30528798 DOI: 10.1016/J.Ejca.2018.10.012 |
0.358 |
|
| 2018 |
Birkbak NJ, Li Y, Pathania S, Greene-Colozzi A, Dreze M, Bowman-Colin C, Sztupinszki Z, Krzystanek M, Diossy M, Tung N, Ryan PD, Garber JE, Silver DP, Iglehart JD, Wang ZC, et al. Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple negative breast and serous ovarian cancers. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29452344 DOI: 10.1093/Annonc/Mdy049 |
0.354 |
|
| 2017 |
Ubellacker JM, Haider MT, DeCristo MJ, Allocca G, Brown NJ, Silver DP, Holen I, McAllister SS. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells. Breast Cancer Research : Bcr. 19: 23. PMID 28264701 DOI: 10.1186/S13058-017-0815-8 |
0.382 |
|
| 2017 |
Telli M, Badve S, Vinayak S, Silver D, Isakoff S, Kaklamani V, Gradishar W, Stearns V, Connolly R, Ford J, Adams S, Garber J, Evans B, Timms K, Wenstrup R, et al. Abstract P6-09-09: Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (TNBC): A pooled analysis Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-09-09 |
0.332 |
|
| 2016 |
Telli ML, Timms KM, Reid JE, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung N, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, ... ... Silver DP, et al. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26957554 DOI: 10.1158/1078-0432.Ccr-15-2477 |
0.317 |
|
| 2015 |
Marquard AM, Eklund AC, Joshi T, Krzystanek M, Favero F, Wang ZC, Richardson AL, Silver DP, Szallasi Z, Birkbak NJ. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomarker Research. 3: 9. PMID 26015868 DOI: 10.1186/s40364-015-0033-4 |
0.373 |
|
| 2015 |
Silver DP, Neupane M, Clark AP, Vidal M, Hill DE. Abstract P4-05-04: MECP2 is a frequently amplified oncogene and potential therapeutic target in TNBC Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-05-04 |
0.337 |
|
| 2015 |
Richardson AL, Silver DP, Szallasi Z, Birkbak NJ, Wang ZC, Iglehart JD, Mayer EL, Winer EP, Tung NM, Ryan PD, Isakoff SJ, Barry WT, Greene-Collozi A, Gutin A, Reid J, et al. Abstract P3-06-11: Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-11 |
0.375 |
|
| 2014 |
Hill SJ, Clark AP, Silver DP, Livingston DM. BRCA1 pathway function in basal-like breast cancer cells. Molecular and Cellular Biology. 34: 3828-42. PMID 25092866 DOI: 10.1128/Mcb.01646-13 |
0.619 |
|
| 2013 |
Birkbak N, Li Y, Bowman-Collin C, Iglehart J, Silver D, Wang Z, Szallasi Z, Richardson A. Gain of Chromosomal Region 15Q26 Cause Increased Expression of BLM and FANCI, and is Associated with Sensitivity to Platinum Chemotherapy in Triple Negative Breast Cancer Annals of Oncology. 24: iii22. DOI: 10.1093/ANNONC/MDT082.3 |
0.37 |
|
| 2012 |
Silver DP, Livingston DM. Mechanisms of BRCA1 tumor suppression. Cancer Discovery. 2: 679-84. PMID 22843421 DOI: 10.1158/2159-8290.Cd-12-0221 |
0.503 |
|
| 2012 |
Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, Menzies A, Martin S, Leung K, Chen L, Leroy C, ... ... Silver D, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 149: 979-93. PMID 22608084 DOI: 10.1016/j.cell.2012.04.024 |
0.341 |
|
| 2012 |
Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discovery. 2: 366-75. PMID 22576213 DOI: 10.1158/2159-8290.CD-11-0206 |
0.356 |
|
| 2011 |
Tung N, Silver DP. Chek2 DNA damage response pathway and inherited breast cancer risk. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3813-5. PMID 21876079 DOI: 10.1200/JCO.2011.37.1476 |
0.356 |
|
| 2010 |
Tung N, Miron A, Schnitt SJ, Gautam S, Fetten K, Kaplan J, Yassin Y, Buraimoh A, Kim JY, Szász AM, Tian R, Wang ZC, Collins LC, Brock J, Krag K, ... ... Silver DP, et al. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Research : Bcr. 12: R95. PMID 21080930 DOI: 10.1186/bcr2776 |
0.426 |
|
| 2010 |
Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, Carey LA. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4702-10. PMID 20858840 DOI: 10.1158/1078-0432.CCR-10-0939 |
0.437 |
|
| 2010 |
Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1145-53. PMID 20100965 DOI: 10.1200/JCO.2009.22.4725 |
0.377 |
|
| 2009 |
Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau KW, ... ... Silver DP, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature. 462: 1005-10. PMID 20033038 DOI: 10.1038/nature08645 |
0.367 |
|
| 2009 |
Zhao JJ, Silver DP. Estrogen receptor-negative breast cancer: new insights into subclassification and targeting. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6309-10. PMID 19825953 DOI: 10.1158/1078-0432.CCR-09-2010 |
0.301 |
|
| 2008 |
Livingston DM, Silver DP. Cancer: crossing over to drug resistance. Nature. 451: 1066-7. PMID 18305536 DOI: 10.1038/4511066A |
0.401 |
|
| 2007 |
Silver DP, Dimitrov SD, Feunteun J, Gelman R, Drapkin R, Lu SD, Shestakova E, Velmurugan S, Denunzio N, Dragomir S, Mar J, Liu X, Rottenberg S, Jonkers J, Ganesan S, et al. Further evidence for BRCA1 communication with the inactive X chromosome. Cell. 128: 991-1002. PMID 17350581 DOI: 10.1016/J.Cell.2007.02.025 |
0.614 |
|
| 2004 |
Ganesan S, Silver DP, Drapkin R, Greenberg R, Feunteun J, Livingston DM. Association of BRCA1 with the inactive X chromosome and XIST RNA. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 359: 123-8. PMID 15065664 DOI: 10.1098/Rstb.2003.1371 |
0.64 |
|
| 2003 |
Silver DP. HIN-1 and the nosology of breast cancer. Cancer Biology & Therapy. 2: 564-5. PMID 14614328 DOI: 10.4161/cbt.2.5.512 |
0.39 |
|
| 2002 |
Ganesan S, Silver DP, Greenberg RA, Avni D, Drapkin R, Miron A, Mok SC, Randrianarison V, Brodie S, Salstrom J, Rasmussen TP, Klimke A, Marrese C, Marahrens Y, Deng CX, et al. BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell. 111: 393-405. PMID 12419249 DOI: 10.1016/S0092-8674(02)01052-8 |
0.633 |
|
| 2001 |
Martelli F, Hamilton T, Silver DP, Sharpless NE, Bardeesy N, Rokas M, DePinho RA, Livingston DM, Grossman SR. p19ARF targets certain E2F species for degradation. Proceedings of the National Academy of Sciences of the United States of America. 98: 4455-60. PMID 11274364 DOI: 10.1073/Pnas.081061398 |
0.434 |
|
| Show low-probability matches. |